Spectranetics Completes AngioScore Acquisition - Quick Facts

(RTTNews) - The Spectranetics Corp. (SPNC) announced that it has completed the acquisition of AngioScore Inc. for $230 million in cash, along with additional contingent commercial and regulatory milestone payments.

AngioScore, based in Fremont, Calif., develops and markets the AngioSculpt scoring balloon technology platform, which is a differentiated, comprehensive portfolio to treat blockages in the coronary and peripheral vasculature. AngioScore's product and distribution platforms diversify Spectranetics' portfolio while expanding physicians' options to treat critical limb ischemia or CLI, in-stent restenosis or ISR, calcified lesions and chronic total occlusions or CTO.